Topical tacrolimus in the treatment of perianal Crohn's disease: Exploratory randomized controlled trial

Inflammatory Bowel Diseases

Volumn 13, Issue 3, 2007, Pages 245-253

  Hart, Ailsa L ^a   Plamondon, Sophie ^a   Kamm, Michael A ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

Author keywords

Crohn's disease; Fistula; Perianal; Tacrolimus; Ulceration

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; PLACEBO; TACROLIMUS;

ABSCESS; ANUS FISTULA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HUMAN; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN BURNING SENSATION; SKIN IRRITATION;

ADMINISTRATION, TOPICAL; ADULT; CROHN DISEASE; DOUBLE-BLIND METHOD; FEMALE; FISSURE IN ANO; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; RECTAL FISTULA; TACROLIMUS;

EID: 33947506701     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20073     Document Type: Article

References (52)

1. Farmer RG, Hawk WA, Turnbull RB Jr. Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology. 1975;68(4):627-635.
2. Schwartz D, Pemberton JH, Sandborn WJ. Diagnosis and treatment of perianal fistulas in Crohn's disease. Ann Intern Med. 2001;135:906-918.
3. Lapidus A, Bernell O, Hellers G, et al. Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients. Gastroenterology. 1998;114:1151-1160.
4. Sandborn WJ, Feagan B, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002;122:512-530.
5. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
6. Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMasters IBD Study Group. J Clin Gastroenterol. 1995;20(1):27-32.
7. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology. 1994;106:287-296.
8. Markowitz J, Grancher K, Rosa J, et al. Highly destructive perianal disease in children with Crohn's disease. J Pediatr Gastroenterol Nutr. 1995;21(2):149-153.
9. Bell SJ, Williams AB, Wiesel P, et al. The clinical course of fistulating Crohn's disease. Alim Pharmacol Ther. 2003;7 (9):1145-1151.
10. Brandt LJ, Bernstein LH, Boley SJ, et al. Metronidazole therapy for perianal Crohn's disease: a follow-up study. Gastroenterology. 1982;83(2):383-387.
11. Bernstein LH, Frank MS, Brandt LJ, et al. Healing of perianal Crohn's disease with metronidazole. Gastroenterology. 1980;79(2):357-365.
12. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol. 1984;79(7):533-540.
13. Biancone L, Pallone F. Current treatment modalities in active Crohn's disease. Ital J Gastroenterol Hepatol. 1999;31(6):508-514.
14. Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol. 1998;93(3):442-448.
15. Santos JV, Baudet JA. Casellas FJ, et al. Intravenous cyclosporine for steroid-refractory attacks of Crohn's disease. Scand J Clin Gastroenterol. 1995;20(3):207-210.
16. Ramakrishna J, Langhans N, Calenda K, et al. Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1996;22(3):296-302.
17. Mahdi G, Israel DM, Hassall E. Cyclosporin and 6-mercaptopurine for active, refractory Crohn's colitis in children. Am J Gastroenterol. 1996;91(7):1355-1359.
18. Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporine A. Am J Gastroenterol. 1993;88(5):646-649.
19. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci. 1994;39(2):374-380.
20. Hinterleitner TA, Petritsch W, Aichbichler B, et al. Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease. Z Gastroenterol. 1997;35(8):603-608.
21. Korelitz BI, Present DH. Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease. Scand J Gastroenterol. 1985;20(10):1197-1203.
22. Nyman M, Hansson I, Eriksson S, Long-term immunosuppressive treatment in Crohn's disease. Scand J Gastroenterol. 1985;20(10):1197-1203.
23. Markowitz J, Rosa J, Grancher K, et al. Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology. 1990;99(5):1347-1351.
24. Lemann M, Bonhomme P, Bitoun A, et al. Treatment of Crohn's disease with azathioprine or 6-mercaptopurine. Retrospective study of 126 cases. Gastroenterol Clin Biol. 1990;14(6/7):548-554.
25. O'Brien JJ, Bayless TM, Bayless JA. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology. 1991;101(1):39-46.
26. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123(2):132-142.
27. Sands BE, Anderson FH, Berstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350(9):876-85.
28. Ruzicka T, Assmann T, Homey B. Tacrolimus: the drug for the turn of the millennium. Arch Dermatol. 1999;135(5):574-580.
29. Van Thiel DH, Carroll P, Abu-Elmagd K, et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol. 1995;90(3):455-459.
30. Stephens J, Goldstein R, Crippin J, et al. Effects of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholangitis patients. Transplant Proc. 1993;25(1 Pt 2):1122-1123.
31. Bousvaros A, Wang A, Leichtner AM. Tacrolimus (FK-506) treatment of fulminant colitis in a child. J Pediatr Gastroenterol Nutr. 1996;23(3):329-333.
32. Bousvaros, A., Kirschner B., Werlin S, et al. Oral tacrolimus treatment of severe colitis in children. Gastroenterology. 2000;112(4):A941.
33. Fellermann K, Ludwig D, Stahl M, et al. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol. 1998;93(10):1860-1866.
34. Thomson AW, Carroll PB, McCauley J, et al. FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh. Springer Semin Immunopathol. 1993;14(4):323-344.
35. Abu-Elmagd K, Jegasothy BV, Ackerman CD, et al. Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. Transplant Proc. 1991;23(6):3328-3329.
36. Abu-Elmagd K, Van Thiel DH, Jegasothy BV, et al. Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK 506). Ann Intern Med. 1993;119(7Pt 1):595-598.
37. Ierardi E, Principi M, Rendina M, et al. Oral tacrolimus (FK506) in Crohn's disease complicated by fistulae of the perineum. J Clin Gastroenterol. 2000;30(2):200-202.
38. Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol. 1997;92(5):876-878.
39. Lowry PW, Weaver AL, Tremaine WJ, et al. Combination therapy with oral tacrolimus (FK 506) and azathioprine or 6-mercaptopurine for the treatment of refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis. 1999;5:239-245.
40. Sandborn WJ, Present DH, Isaacs L, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology. 2003;125:380-388.
41. Gonzalez-Lama, Alsreu L, Vera MJ, et al. Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease: a pilot study. Inflamm Bowel Dis. 2005;11(1):8-15.
42. Remitz A, Reitamo S, Erkko P, et al. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol. 1999;141(1):103-107.
43. Fleischer AB Jr. Treatment of atopic dermatitis: role of tacrolimus ointment as a topical noncorticosteroidal therapy. J. Allergy Clin. Immunol. 1999;104(3 Pt 2):S126-S130.
44. Nakagawa H, Etoh T, Ishibashi Y, et al. Tacrolimus ointment for atopic dermatitis [letter]. Lancet 1994;344(8926):883.
45. Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med. 1997;337(12):816-821.
46. Lauerma AI, Maibach HI, Granlund H, et al. Inhibition of contact allergy reactions by topical FK506 [letter]. Lancet 1992;340(8818):556.
47. Vente C, Reich K, Rupprecht R, et al. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br J Dermatol. 1999;140(2):338-342.
48. Lyon CC, Smith AJ, Beck MH, et al. Parastomal pyoderma gangrenosum: clinical features and management. J Am Acad Dermatol. 2000;42(6):992-1002.
49. Michel G, Kemeny L, Homey B, et al. FK506 in the treatment of inflammatory skin disease: promises and perspectives. Immunol Today. 1996;17(3):106-108.
50. Lauerma AI, Surber C, Maibach HI. Absorption of topical tacrolimus (FK506) in vitro through human skin: comparison with cyclosporin A. Skin Pharmacol. 1997;10(5/6):230-234.
51. Casson DH, Eltumi M, Tomlin S, et al. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut. 2000;47(3):436-440.
52. Poggioli G, Laureti S, Pierangeli F, et al. Local injection of infliximab for the treatment of perianal Crohn's disease. Dis Colon Rectum. 2005;48(4):768-774.